Takeda Pharmaceutical Company Limited (TKDA) - Total Liabilities
Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has total liabilities worth €7.34 Trillion EUR as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Takeda Pharmaceutical Company Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Takeda Pharmaceutical Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Takeda Pharmaceutical Company Limited Competitors by Total Liabilities
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hartford Financial Services Group
NYSE:HIG
|
USA | $67.02 Billion |
|
Oil & Natural Gas Corporation Limited
NSE:ONGC
|
India | Rs3.80 Trillion |
|
ArcelorMittal SA
MC:MTS
|
Spain | €41.17 Billion |
|
Block, Inc
NYSE:XYZ
|
USA | $16.71 Billion |
|
Marubeni Corporation
F:MAR0
|
Germany | €5.27 Trillion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
Sweden | Skr3.44 Trillion |
|
Erste Group Bank AG
VI:EBS
|
Austria | €333.91 Billion |
|
JD.com Inc.
F:013C
|
Germany | €409.11 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Takeda Pharmaceutical Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Takeda Pharmaceutical Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual total liabilities of Takeda Pharmaceutical Company Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €7.31 Trillion | -6.67% |
| 2024-03-31 | €7.83 Trillion | +3.05% |
| 2023-03-31 | €7.60 Trillion | +1.45% |
| 2022-03-31 | €7.49 Trillion | -3.11% |
| 2021-03-31 | €7.74 Trillion | -4.43% |
| 2020-03-31 | €8.09 Trillion | -7.06% |
| 2019-03-31 | €8.71 Trillion | +316.87% |
| 2018-03-31 | €2.09 Trillion | -13.20% |
| 2017-03-31 | €2.41 Trillion | -- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more